Clinical trials: Central Vein Obstruction
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Childhood Cancer, Central Venous Catheters
Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
The primary hypothesis of this study is that occult catheter-related DVT in children with cancer is common and directly contributes to development of serious catheter complications, specifically bacteremia/fungemia and/or…
- Conditions
- Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection
- Trial name
- DVT (NCT00633061)
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- University of Texas Southwestern Medical Center
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Glaucoma, New Onset Glaucoma
Lucentis for New Onset Neovascular Glaucoma
Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abnormal blood vessels.
- Conditions
- Glaucoma, New Onset Glaucoma, Neovascular Glaucoma, New Onset Neovascular Glaucoma
- Trial name
- NVG (NCT00727038)
- Testing
- Ranibizumab (Lucentis)
- Sponsor
- University of Illinois Chicago
Retinal Vein Occlusion
Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema)…
- Trial name
- RETRO CRVO (NCT02645747)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Belgium
- Volunteers
- 126 people
- Sponsor
- Bayer
Central Retinal Vein Occlusion
Phase I RVC With Ocriplasmin for CRVO
In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and neovascularization.
- Trial name
- RVC_CRVO (NCT02747030)
- Testing
- Ocriplasmin intravenously
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Venous Stenosis, Venous Occlusion
The Merit WRAPSODY AV Access Efficacy Study (WAVE)
The purpose of the study is to demonstrate the safety and efficacy of the Merit WRAPSODY Endovascular Stent Graft for treatment of stenosis or occlusion within the dialysis access outflow circuit
- Trial name
- WAVE (NCT04540302)
- Testing
- Merit WRAPSODY Endovascular Stent Graft, PTA
- Where
- 43 sites in United States, Brazil and 2 more
- Volunteers
- 357 people
- Sponsor
- Merit Medical Systems, Inc.
Central Retinal Vein Occlusion
Lucentis for Central Retinal Vein Occlusion (CRVO)
The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
- Trial name
- NCT00406796
- Testing
- Ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- California Retina Consultants
Central Retinal Vein Occlusion
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal…
- Trial name
- NCT04601701
- Testing
- Bevacizumab Ophthalmic and Intravitreal Dexamethasone., Bevacizumab Ophthalmic.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Eye Hospital
Macular Edema, Central Retinal Vein Occlusion
Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
- Trial name
- MECROV (NCT00566761)
- Testing
- bevacizumab and triamcinolone
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Central Retinal Vein Occlusion, Non-Ischemic
Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.
The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion.
- Trial name
- PNPRO_HC (NCT02957760)
- Testing
- Hydroxycarbamid
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Retinal Vein Occlusion, Macular Edema
Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
This study aims to assess if Lucentis injection applied into the eye is superior to conventional treatment concerning the prevention of visual loss in patients having clinically significant macular edema secondary to retinal vein…
- Trial name
- BRAVO (NCT01123564)
- Testing
- ranibizumab, Argon laser treatment
- Where
- 2 sites in Hungary
- Volunteers
- 40 people
- Sponsor
- University of Pecs
Retinal Vein Occlusion
Minocycline to Treat Central Retinal Vein Occlusion
Background: Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye.
- Trial name
- NCT01468844
- Testing
- Minocycline, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Macular Degeneration, Diabetic Macular Edema
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
The purpose of this study is to assess the sensation of ocular dry eye symptom after an intravitreal injection of anti-VEGF.
- Conditions
- Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- PISO (NCT06262737)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Retinal Vein Occlusion, Retinal Diseases
Central Vein Occlusion Study (CVOS)
To determine whether photocoagulation therapy can help prevent iris neovascularization in eyes with central vein occlusion (CVO) and evidence of ischemic retina.
- Trial name
- NCT00000131
- Testing
- Photocoagulation Therapy
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema, Age Related Macular Degeneration
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
Diabetic macular edema (DME), wet-AMD and macular edema secondary to vein occlusions are the leading cause of blindness in developed countries.
- Conditions
- Diabetic Macular Edema, Age Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema
- Trial name
- NCT02556723
- Testing
- Intravitreal injections of ziv-aflibercept
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Retina Clinic, Sao Paulo, Brazil
Central Retinal Vein Occlusion
The ROVO Study: Radial Optic Neurotomy for CVO
The ROVO study is a prospective, placebocontrolled and randomised study designed to evaluate the effect of radial optic neurotomy in central vein occlusion, versus triamcinolone acetonide.
- Trial name
- NCT00532142
- Testing
- Intravitreal Triamcinolone, Radial Optic Neurotomy
- Where
- Austria
- Sponsor
- Rudolf Foundation Clinic